Eribulin versus dacarbazine in patients with leiomyosarcoma: subgroup analysis from a phase 3, open-label, randomised study

Blay, J. Y., Schoffski, P., Bauer, S., Krarup-Hansen, A., Benson, C., D'Adamo, D. R., Jia, Y., Maki, R. G. (May 2019) Eribulin versus dacarbazine in patients with leiomyosarcoma: subgroup analysis from a phase 3, open-label, randomised study. Br J Cancer, 120 (11). pp. 1026-1032. ISSN 0007-0920

URL: https://www.ncbi.nlm.nih.gov/pubmed/31065111
DOI: 10.1038/s41416-019-0462-1

Abstract

BACKGROUND: This subgroup analysis of a phase 3 study compares outcomes for eribulin versus dacarbazine in patients with leiomyosarcoma. METHODS: Patients >/=18 years old with advanced liposarcoma or leiomyosarcoma, ECOG PS </=2, and >/=2 prior treatment regimens were randomly assigned (1:1) to eribulin mesylate (1.4 mg/m(2) intravenously on day 1 and day 8) or dacarbazine (either 850, 1000, or 1200 mg/m(2) intravenously) every 21 days until disease progression. The primary end point was OS; secondary end points were progression-free survival (PFS) and objective response rate (ORR). RESULTS: 309 Patients with leiomyosarcoma were included (eribulin, n = 157; dacarbazine, n = 152). Median age was 57 years; 42% of patients had uterine disease and 57% had nonuterine disease. Median OS was 12.7 versus 13.0 months for eribulin versus dacarbazine, respectively (hazard ratio [HR] = 0.93 [95% CI 0.71-1.20]; P = 0.57). Median PFS (2.2 vs 2.6 months, HR = 1.07 [95% CI 0.84-1.38]; P = 0.58) and ORR (5% vs 7%) were similar between eribulin- and dacarbazine-treated patients. Grade >/=3 TEAEs occurred in 69% of patients receiving eribulin and 59% of patients receiving dacarbazine. CONCLUSIONS: Efficacy of eribulin in patients with leiomyosarcoma was comparable to that of dacarbazine. Both agents had manageable safety profiles.

Item Type: Paper
Subjects: diseases & disorders > cancer > drugs and therapies > chemotherapy
diseases & disorders > cancer > cancer types > sarcoma
CSHL Authors:
Communities: CSHL labs > Maki lab
Depositing User: Matthew Dunn
Date: 8 May 2019
Date Deposited: 29 May 2019 18:06
Last Modified: 22 Jul 2019 15:20
Related URLs:
URI: http://repository.cshl.edu/id/eprint/37822

Actions (login required)

Administrator's edit/view item Administrator's edit/view item
CSHL HomeAbout CSHLResearchEducationNews & FeaturesCampus & Public EventsCareersGiving